Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

Abramson Cancer Center at Penn Medicine logo

Abramson Cancer Center at Penn Medicine

Status

Terminated

Conditions

Non-Hodgkin Lymphoma

Treatments

Diagnostic Test: 2-Deoxy-2-[18F]fluoro-D-glucose (FDG)

Study type

Observational

Funder types

Other

Identifiers

NCT03065790
UPCC 54416

Details and patient eligibility

About

Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adult patients, at least 18 years of age
  • History of histologically confirmed NHL as assessed per medical record review.
  • At least one site of measurable disease (per RECIST 1.1) that is seen on CT, MRI, or FDG PET/CT.
  • Recommended to start lenalidomide.
  • Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion criteria

  • Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine or serum pregnancy test at the time of the screening visit.
  • Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.
  • Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems